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CBackground: Shortened courses of treatment with pegylated inter-
feron alfa and ribavirin for patientswith hepatitis C virus infectionwho
experience rapid virologic response can be effective in appropriately
selected patients. The cost-effectiveness of truncated therapy is not
known.Objective: To assess the cost-effectiveness of response-guided
therapy versus standard-duration therapy on the basis of best available
evidence. Methods: We developed a decision model for chronic hepa-
titis C virus infection representing two treatment strategies: 1) stan-
dard-duration therapy with pegylated interferon alfa and ribavirin for
48 weeks in patients with genotype 1 or 4 and for 24 weeks in patients
with genotype 2 or 3 and 2) truncated therapy (i.e., 50% decrease in
treatment duration) in patients with rapid virologic response. Patients
for whom truncated therapy failed began standard-duration therapy
guided by genotype.Weused aMarkovmodel to estimate lifetime costs
and quality-adjusted life-years. Results: In the base-case analysis,
mean lifetime costs were $46,623  $2,483 with standard-duration O
h Ins
al So
ttp://dx.doi.org/10.1016/j.jval.2012.06.010herapy and $42,354  $2,489 with truncated therapy. Mean lifetime
uality-adjusted life-years were similar between the groups (17.1 0.7
ith standard therapy; 17.2  0.7 with truncated therapy). Across
odel simulations, the probability of truncated therapy being eco-
omically dominant (i.e., both cost saving and more effective) was
8.6%. The results were consistent when we stratified the data by
enotype. In one-way sensitivity analyses, the results were sensitive
nly to changes in treatment efficacy. Conclusion: Truncated ther-
py based on rapid virologic response is likely to be cost saving for
reatment-naive patientswith chronic hepatitis C virus infection. Cost-
ffectiveness varied with small changes in relative treatment efficacy.
eywords: chronic, cost-effectiveness, hepatitis C, interferon alfa-2a,
nterferon alfa-2b, personalized therapy, response-guided therapy,
ibavirin, treatment outcome.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
It is estimated that 2% of the world’s population is infected with
hepatitis C virus (HCV), representingmore than 170million people
[1]. Antiviral therapy with pegylated interferon alfa and ribavirin
has shown moderate success in the treatment of patients with
chronic HCV infection, although treatment is associated with sig-
nificant costs and potential side effects [2,3].
Current guidelines in the United States recommend that pa-
tients receive a combination of pegylated interferon alfa and riba-
virin for durations that vary on the basis of viral genotype. Patients
with genotype 1 or 4 receive treatment for 48 weeks; patients with
genotype 2 or 3 receive treatment for 24 weeks [4]. In contrast, the
most recent guidelines from the European Association for the
Study of the Liver [5] recommend that shorter courses of antiviral
therapy guided by rapid virologic response (i.e., undetectable viral
RNA at week 4) should be considered in appropriately selected
patients.
* Address correspondence to: Ziad F. Gellad, Duke Clinical Researc
E-mail: ziad.gellad@duke.edu.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.These recommendations are based on data from both observa-
tional analyses and randomized clinical trials in which the strength
of association between rapid virologic response and sustained viro-
logic response was mixed [6–25]. Furthermore, it is unclear whether
thepotential short-termbenefits to patients andhealth care systems
in reducing treatment duration are offset by a higher proportion of
patients who do not have sustained virologic response and experi-
ence long-term complications of hepatitis. Nevertheless, clinical
consensus inmany countries, as representedby the Europeanguide-
lines, now recommend basing the duration of treatment on rapid
virologic response and genotype, also known as response-guided
therapy. Thus, the goal of our analysis was to assess the cost-effec-
tiveness of response-guided therapy versus standard-duration ther-
apy on the basis of best available evidence. Although response-
guided therapy has not been adopted in the United States, this
analysis may help providers evaluate the balance of short-term and
long-termcostsandbenefitsof response-guided therapyandprovide
guidance for the design of future studies to validate the use of rapid
virologic response as an actionable biomarker.
titute, PO Box 17969, Durham, NC 27715.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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In a decision-analytic model (Fig. 1), we compared standard-dura-
tion therapy with response-guided therapy in a hypothetical pop-
ulation of treatment-naive patients with chronic HCV infection. In
the standard-duration arm, patients with viral genotype 1 or 4
received ribavirin and pegylated interferon alfa for 48 weeks and
patients with genotype 2 or 3 received the same therapy for 24
weeks. Treatment of patients with genotype 1 or 4 was halted at
week 12 if the patient did not experience early virologic response
(i.e., had 2 log reduction in viral RNA at week 12). Patients with
genotype 2 or 3 received 24 weeks of therapy regardless of viral
kinetics.
In the response-guided arm, the duration of therapy varied on
the basis of genotype, baseline viral load for patients with geno-
type 1, and rapid virologic response at week 4. Treatment duration
was truncated by 50% for patients with genotype 1 and low viral
load (600,000 IU/mL) and for patients with genotypes 2, 3, or 4
who experienced rapid virologic response. Patients with genotype
1 and high viral load stopped treatment at week 12 or 24 if re-
sponse to therapy was inadequate (i.e., 2 log reduction in viral
RNA atweek 12 or detectable viral RNA atweek 24). The remaining
patients in the genotype 1 group without rapid virologic response
continued with the full course (i.e., 48 weeks) of treatment. Pa-
tients for whom truncated therapy failed were re-treated with
standard-duration therapy (i.e., 24 or 48 weeks) guided by viral
genotype.
Probabilities of treatment efficacy
Table 1 shows the probabilities used in the decision tree. An inter-
national panel of physicians with expertise in viral hepatitis re-
viewed the published literature for reports comparing the efficacy
of standard-duration and response-guided therapy [6–25]. When
possible, we selected base-case probabilities and standard errors
from a single source in which all relevant probabilities within a
Fig. 1 – Decision tree for standard-duration therapy and resp
viral load; LVL, low viral load; nRVR, no rapid virologic respo
virologic response; SVR, sustained virologic response.genotype were available. For genotype 1, no randomized trial con-tained both viral kinetic data and rates of sustained virologic re-
sponse. Thus, we obtained the majority of our estimates from the
Individualized Dosing Efficacy vs. Flat Dosing to Assess Optimal
Pegylated Interferon Therapy study [26]. We selected this study
because the study sponsor provided robust data on viral kinetics,
which are critical to the decision model. Because the Individual-
ized Dosing Efficacy vs. Flat Dosing to Assess Optimal Pegylated
InterferonTherapy trial did not evaluate outcomeswith shortened
antiviral therapy, we applied the rate of sustained virologic re-
sponse conditional on having experienced rapid virologic re-
sponse from a trial designed to test the efficacy of truncated ther-
apy [25]. We selected these rates so that the overall rates of
sustained virologic response in the standard-duration and re-
sponse-guided therapy groups would be similar, consistent with a
recent meta-analysis [27].
For genotypes 2 and 3, we obtained estimates of treatment
efficacy for standard and truncated therapy from a 2008 meta-
analysis by Andriulli et al. [6]. Again, because this source did not
report viral kinetics,we used data on rapid virologic response from
one of the randomized trials included in the meta-analysis and
varied this probabilitywidely in the sensitivity analysis [23]. Treat-
ment efficacy data for genotype 4 were derived from a single pub-
lished randomized trial [13].
We determined probability ranges on the basis of a review of all
available evidence, summarized in Table 1. When relevant alter-
native estimates were not found (i.e., probability of early virologic
response in patients with high viral load, probability of 24-week
response in patients with high viral load, and probability of sus-
tained virologic response in patients with high viral load), we es-
timated ranges as 20% higher or lower than the baseline value. For
response-guided therapy, we assumed that the probability of sus-
tained virologic response with re-treatment after failed truncated
therapy was 20% in the base-case model and varied this value
widely in sensitivity analyses. Finally, we did not assume long-
term treatment benefit for patients who experienced relapse and
e-guided therapy. EVR, early virologic response; HVL, high
; nSVR, no sustained virologic response; RVR, rapidons
nsefor whom re-treatment failed.
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The decision tree apportioned a hypothetical cohort of patients
into two health states at 48 weeks on the basis of response to
therapy: sustained virologic response or chronic active HCV infec-
tion, the latter representing patients who relapsed or did not re-
spond to therapy. The distribution of genotypes was derived from
population-based data [7,20,28]. We used a Markov model to cal-
ulate remaining lifetime costs and quality-adjusted life-years
QALYs) (Fig. 2). The Markov model used in this analysis is based
n a previously published model [29] that we restructured and
updated to reflectmodern therapy for chronic liver disease and its
complications. Specifically, we added liver transplant as a treat-
ment option for hepatocellular carcinoma, we added health states
for baseline liver fibrosis to better reflect the natural history of
HCV infection, and we updated transition probabilities to reflect
the improved effectiveness of currently available therapies for en-
cephalopathy, ascites, varices, and hepatocellular carcinoma.
We conducted the analysis froma limitedUS societal perspective
andappliedacycle lengthof 1year.Wediscountedcostsandbenefits
at a rate of 3%per year [30].WeusedTreeAge Pro Suite 2009 (TreeAge
Software, Williamstown, MA) for model creation and analyses.
Patient characteristics
Themodel cohort consisted of patients aged 40 years with chronic
Table 1 – Probabilities of treatment efficacy and distributio
Variable Probability (S
Genotype 1 80 (—)
Standard-duration therapy
EVR 73 (0.98
SVR given EVR 54 (1.3)
Response-guided therapy
LVL 18 (0.84
RVR in LVL 39 (2.6)
SVR in LVL given RVR 89 (3.0)
EVR in LVL given no RVR 75 (2.9)
SVR in LVL given no RVR, EVR 61 (3.8)
EVR in HVL 71 (1.1)
24-week response in HVL given EVR 75 (1.3)
SVR in HVL given EVR, 24-week response 64 (1.6)
Genotype 2 12.7 (—)
Standard-duration therapy
SVR 75 (1.4)
Response-guided therapy
RVR 69 (1.7)
SVR given RVR 83 (1.7)
SVR given nRVR 62 (3.4)
Genotype 3 6.2 (—)
Standard-duration therapy
SVR 69 (1.3)
Response-guided therapy
RVR 62 (1.8)
SVR given RVR 83 (1.7)
SVR given nRVR 46 (2.9)
Genotype 4 1.1 (—)
Standard-duration therapy 60
EVR 68 (6.6)
SVR given EVR 88 (5.5)
Response-guided therapy 73
RVR 21 (2.1)
SVR given RVR 86 (4.2)
EVR given nRVR 91 (1.7)
SVR given nRVR, EVR 77 (8.3)
EVR, early virologic response; HRL, high viral load; LVL, low viral loa
sustained virologic response.HCV infection, of whom 60% were men. Follow-up lasted 60 yearsor until death. Patients hadno contraindications to therapy andno
clinically significant comorbid conditions, including other viral in-
fections (e.g., HIV, hepatitis B) or alcohol abuse. Because the risk of
complications from chronic liver disease depends on the degree of
fibrosis, patients were distributed across health states represent-
ing different Metavir fibrosis scores [31], and we assumed that
patients with compensated cirrhosis developed decompensation
before liver disease–related death.
Annual transition probabilities
Table 2 shows the annual transition probabilities for the Markov
model. In everyhealth state, patientswereat riskofdeathnot related
to liver disease. Wemodeled this risk by using age- and sex-specific
mortality rates from US life tables [32]. In addition, patients with
chronic liver disease were at risk of liver disease–related death once
decompensation occurred. Patients with sustained virologic re-
sponse were only at risk of death not related to liver disease.
Natural history of hepatitis C
Estimates of the natural history of fibrosis progression in HCV
infection were derived from a recently published meta-analysis
[33]. No spontaneous clearance of HCV was observed. In patients
who progressed to cirrhosis, the annual rate of decompensation
was driven by the development of four potential complications:
genotypes in the decision tree.
Reference Range, % References
20 72–80 7, 28
26 73–96 10, 11, 18, 25
26 54–85 10, 11, 18, 25
26 8–24 10, 11, 18, 25
26 27–51 10, 11, 18, 25
25 74–96 10, 11, 18
26 75–78 10, 11, 18, 25
26 51–61 10, 11, 18, 25
26 57–85 10, 11, 18, 25
26 60–90 10, 11, 18, 25
26 51–77 10, 11, 18, 25
20 13–14 7, 28
6 75–82 8, 16, 17, 19, 23, 24
23 62–97 8, 16, 17, 19, 23, 24
6 78–93 8, 16, 17, 19, 23, 24
6 53–72 8, 16, 17, 19, 23, 24
20 5.5–8.0 7, 28
6 66–78 8, 16, 17, 19, 23, 24
23 59–92 8, 16, 17, 19, 23, 24
6 77–85 8, 16, 17, 19, 23, 24
6 39–46 8, 16, 17, 19, 23, 24
20 0.50–11 7, 28
Calculated
13 68–79 9–15, 21
13 71–100 9–15, 21
Calculated
13 21–45 9–15, 21
13 86–100 9–15, 21
13 65–91 9–15, 21
13 50–77 9–15, 21
VR, no rapid virologic response; RVR, rapid virologic response; SVR,n of
E), %
)
)
d; nRascites, variceal hemorrhage, hepatic encephalopathy, and hepa-
p879V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 7 6 – 8 8 6tocellular carcinoma [22,29,34]. Once patients experienced decom-
pensation, they had a risk of death driven by that particular com-
plication [34–40]. For the purposes of the analysis, we assumed
that patients developed only a single complication in the course of
their disease. To account for the fact that the risk of death from
complications is highest in the first year of decompensation, we
created additional health states for patients who survived the first
year of a variceal hemorrhage and hepatic encephalopathy and for
patients with ascites that became refractory to medication.
Liver transplant
Orthotopic liver transplant was available for patients with decom-
pensated cirrhosis and patients with hepatocellular carcinoma.
We modeled the annual probability of liver transplantation for
those with decompensated cirrhosis on the basis of estimates
from a sample of patients with decompensated HCV infection [29]
and planned that the sensitivity analyses would cover a wide
range of possible values.We derived estimates of the annual prob-
ability of undergoing liver transplant for patients with hepatocel-
lular carcinoma from a large single-center series of patients [41].
Sustained virologic
response
Chronic HCV infection
(Metavir F0)
Chronic HCV infection
(Metavir F1)
Hepatocellular
carcinoma
Compensated
cirrhosis
Diuretic-sensitive
ascites
Variceal bleeding,
first year
Variceal bleeding,
> 1 year
Hepatic
encephalopathy,
first year
Hepatic
encephalopathy,
> 1 year
Refractory ascites
Fig. 2 – Schematic of the Markov model of chronic hepatitis
any state after chronic HCV infection with stage F3 fibrosis (
(age-standardized) may occur from any state (arrows not sh
SVR, sustained virologic response.The risk of death after liver transplantwas based primarily on datafrom the United Network for Organ Sharing [42] for transplants
erformed between 1996 and 2006 [43,44].
Quality of life
Estimates of quality of life were based on published utility weights
[45–48] (Table 3). To match the health states with those described
by Chong et al. [45], we assumed that all decompensated health
states in the model had the same utility (0.60). We also assumed
thatMetavir fibrosis scores F0 and F1 indicated “mild hepatitis,” F2
indicated “moderate hepatitis,” and F3 and F4 indicated “compen-
sated cirrhosis.” Finally, we multiplied the utility weights for mild
hepatitis, moderate hepatitis, and cirrhosis by 0.90 (range 0.85–
0.95) during antiviral treatment to account for decrements in qual-
ity of life resulting from medication side effects [49].
Costs
Costs in thisanalysiswere limited todirectmedical costs.The impact
of lost productivitywas assumed to be reflected in the utilityweights
[50]. The analysis also excluded costs associated with non–liver-re-
Chronic HCV infection
(Metavir F2)
Chronic HCV infection
(Metavir F3)
Death not from
liver disease
(age-standardized)
Death from
liver disease
Liver transplant,
first year
Liver transplant,
> 1 year
te. Transition to death from liver disease may occur from
s not shown). Transition to death not from liver disease
). HCC, hepatocellular carcinoma; HCV, hepatitis C virus;C. No
arrow
ownlated health states. All costs are expressed in 2010 US dollars.
880 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 7 6 – 8 8 6Table 3 shows the costs associatedwith eachhealth state in the
Markov model. We generated cost estimates by using assump-
tions about the annual frequency of clinic visits in each health
state and associated diagnostic and therapeutic procedures [29,51]
Table 2 – Annual transition probabilities and base-case ass
Variable
Annual transition probabilities (SE), %
Metavir fibrosis score F0 to F1
Metavir fibrosis score F1 to F2
Metavir fibrosis score F2 to F3
Metavir fibrosis score F3 to
Compensated cirrhosis
Hepatocellular carcinoma
Compensated cirrhosis to
Diuretic-sensitive ascites
Variceal hemorrhage
Hepatic encephalopathy
Hepatocellular carcinoma
Diuretic-sensitive ascites to
Refractory ascites
Death from liver disease
Diuretic refractory ascites to death from liver disease
Variceal hemorrhage (year 1) to death from liver disease
Variceal hemorrhage ( 1 year) to death from liver disease
Hepatic encephalopathy (year 1) to death from liver disease
Hepatic encephalopathy ( 1 year) to death from liver disease
Hepatocellular carcinoma to
Liver transplant
Death from liver disease
Decompensated cirrhosis to liver transplant (year 1)
Liver transplant (year 1) to death from liver disease
Liver transplant ( 1 year) to death from liver disease
Input variables
Discount rate, %
Age, y
Male, %
Metavir fibrosis score, %
Chronic F0
Chronic F1
Chronic F2
Chronic F3
F4 (cirrhosis)
Table 3 – Costs and utilities for health states in the Markov
Health state Costs, $*
Base value (Range)
First year after treatment 491 (246–982)
SVR in subsequent years 82 (41–164)
Mild chronic hepatitis C 164 (82–327)
Moderate chronic hepatitis C 164 (82–327)
Compensated cirrhosis 665 (333–1331)
Diuretic-sensitive ascites 4334 (2167–8668)
Refractory ascites 22,320 (11,160–44,640)
Variceal hemorrhage (year 1) 32,982 (16,491–65,964)
Variceal hemorrhage ( 1 y) 5639 (2820–11,278)
Hepatic encephalopathy (year 1) 26,714 (13,357–53,428)
Hepatic encephalopathy ( 1 y) 6639 (3320–13,278)
Hepatocellular carcinoma 40,843 (20,422–81,686)
Liver transplant (year 1) 154,764 (77,382–309,528)
Liver transplant ( 1 y) 29,000 (14,500–58,000)
* Costs are expressed in 2010 US dollars.
† Utilities are multiplied by 0.90 (range, 0.85–0.95) during treatment.(Table 4). Drug costs are based on average wholesale prices. We
used generic formulations, when available [52]. Finally, for inpa-
tient costs, we assigned International Classification of Diseases, Ninth
Revision, Clinical Modification codes or diagnosis-related group
tions.
Base value Range References
12 (0.50) 6.5–12 33
8.5 (0.40) 5.9–9.0 33
12 (0.50) 11–13 33
12 (0.40) 7.7–12 33
0.1 (—) 0.0–1.0 Assumption
2.8 (0.46) 2.0–12.0 22, 34
0.3 (0.46) 0.10–6.0 22, 34
0.1 (0.08) 0.10–4.0 22, 34
3.7 (0.51) 0.10–5.0 22, 34
67 (2.4) 3.0–13 36, 38
11 (3.0) 5.0–20 36, 38
31 (8.4) 23–48 37, 39
39 (8.8) 35–45 35, 37
14 (0.59) 0.50–30 35, 37
64 (3.7) 55–75 34
29 (5.8) 20–40 34
2.0 (—) 0.0–5.0 41
66 (2.4) 60–90 40
3.1 (—) 0.0–5.0 Assumption
12 (0.40) 10–21 42–44
5.0 (0.26) 4.0–6.0 42–44
3.0 0.0–5.0 30
40 20–60 Assumption
60 40–80 Assumption
10 3–11 31
36 24–37 31
21 21–28 31
15 15–26 31
18 9–18 31
del.
Utilities†
erences Base value (SE) Range References
1–53 0.86 (0.04) 0.82–0.98 45–48
1–53 0.86 (0.04) 0.82–0.98 45–48
1–53 0.79 (0.04) 0.77–0.95 45–48
1–53 0.79 (0.04) 0.66–0.92 45–48
1–53 0.80 (0.05) 0.55–0.89 45–48
1–53 0.80 (0.05) 0.55–0.89 45–48
1–53 0.60 (0.12) 0.46–0.71 45–48
1–53 0.60 (0.12) 0.46–0.71 45–48
1–53 0.60 (0.12) 0.46–0.71 45–48
1–53 0.60 (0.12) 0.46–0.71 45–48
1–53 0.60 (0.12) 0.46–0.71 45–48
1–53 0.72 (0.05) 0.20–0.72 45–48
1–53 0.73 (0.05) 0.45–0.86 45–48
1–53 0.73 (0.05) 0.67–0.73 45–48umpmo
Ref
5
5
5
5
5
5
5
5
5
5
5
5
5
5
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Resource use by health state Frequency Annual cost, $
Sustained virologic response, first year after treatment
Outpatient visit Every 4 months 297
Laboratory evaluations Every 4 months 194
Total annual cost — 491
Sustained virologic response, subsequent years
Outpatient visit Every 2 years 50
Laboratory evaluations Every 2 years 32
Total annual cost — 82
Mild/moderate chronic hepatitis C
Outpatient visit Every 1 year 99
Laboratory evaluations Every 1 year 65
Total annual cost — 164
Compensated cirrhosis
Outpatient visit (level 4) Every 6 months 198
Laboratory evaluations Every 6 months 129
Endoscopy Every 1 year 204
Ultrasound Every 1 year 134
Total annual cost — 665
Diuretic-sensitive ascites, first year
Outpatient visit Every 3 months 396
Laboratory evaluations Every 3 months 258
Endoscopy Every 1 year 204
Ultrasound Every 1 year 134
Inpatient admission Every 3 years 2452
Medications Every 1 year 734
Paracentesis Every 1 year 155
Total annual cost — 4334
Refractory ascites, subsequent years
Outpatient visits Every 2 months 594
Laboratory evaluations Every 2 months 388
Endoscopy Every 1 year 204
Ultrasound Every 1 year 134
Inpatient admission Every 5 months 17,674
Medications Every 1 year 1469
Paracentesis Every 1 month 1858
Total annual cost — 22,320
Variceal bleeding, first year
Outpatient visits Every 2 months 594
Laboratory evaluations Every 2 months 388
Ultrasound Every 1 year 134
Inpatient admission Every 5 months 30,598
Medications Every 1 year 383
Endoscopy and ligation Every 3 months 885
Total annual cost — 32,983
Variceal bleeding, subsequent years
Outpatient visits Every 3 months 396
Laboratory evaluations Every 3 months 258
Ultrasound Every 1 year 134
Inpatient admission Every 3 years 4246
Medications Every 1 year 383
Endoscopy or ligation Every 1 year 221
Total annual cost — 5639
Encephalopathy, first year
Outpatient visits Every 2 months 594
Laboratory evaluations Every 2 months 388
Endoscopy Every 1 year 204
Ultrasound Every 1 year 134
Inpatient admission Every 5 months 23,129
Medications Every 1 year 2110
Paracentesis Every 1 year 155
Total annual cost — 26,714(continued on next page)
882 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 7 6 – 8 8 6codes to each health state, and we obtained the costs associated
with each of these codes fromweighted national estimates of hos-
pital costs in the Nationwide Inpatient Sample [53].
Costs of antiviral therapy in the model are shown in Table 5.
We made several assumptions about antiviral therapy. First, half
the population received pegylated interferon alfa-2a and half re-
ceived alfa-2b. Second, all patients received generic ribavirin at a
cost equivalent to the mean of 1000 mg and 1200 mg per day.
Third, when weight-based dosing was required for pegylated in-
terferon alfa-2b, we averaged costs across three weight groups
Table 4 (continued)
Resource use by health state
Encephalopathy, subsequent years
Outpatient visits
Laboratory evaluations
Endoscopy
Ultrasound
Inpatient admission
Medications
Total annual cost
Hepatocellular carcinoma
Inpatient admission
Outpatient visit
Laboratory evaluations
Medications
Paracentesis
Total annual cost
Liver transplant, first year
Transplant admission
Other inpatient
Outpatient visit
Laboratory evaluations
Medications
Total annual cost
Liver transplant, subsequent years
Inpatient admission
Outpatient visit
Laboratory evaluations
Medications
Re-transplant (5% probability)
Total annual cost
* Laboratory evaluations include complete blood count cell count, b
thromboplastin time test, and alpha-fetoprotein test.
Table 5 – Treatment costs.
Variable Assumptio
Pretreatment costs 1 new outpatient visit and
abdominal ultrasound; l
laboratory costs
Drug monitoring and follow-up costs
12 weeks Outpatient visits with labo
2 weeks; pregnancy test
HCV RNA test every 12 w
contraception costs 36 w
24 weeks Outpatient visits with labo
2 weeks; pregnancy test
HCV RNA test every 12 w
contraception costs 48 w
48 weeks Outpatient visits with labo
2 weeks; pregnancy test
HCV RNA every 12 week
costs 72 weeks
HCV RNA
Antiviral treatment Weekly(i.e., 50 kg, 75 kg, and 100 kg). The cost of antiviral therapy in the
base-case analysis was the average wholesale price minus 19.5%
[54]. The upper range was the average wholesale price, and the
lower range was based on the Federal Supply Schedule [55].
Sensitivity analyses
To assess the robustness of our assumptions, we performed one-
way sensitivity analyses of all variables. These analyses were
based on comparisons of net monetary benefit [56] and a willing-
Frequency Annual cost, $
Every 2 months 594
Every 2 months 388
Every 1 year 204
Every 1 year 134
Every 3 years 3209
Every 1 year 2110
— 6639
Every 6 months 34,685
Every 3 months 396
Every 3 months 258
Every 1 year 5349
Every 1 year 155
— 40,843
Once 72,209
Every 5 months 57,912
Every 1 month 1189
Every 1 month 775
Every 1 year 22,678
— 154,764
Every 9 months 9568
Every 2 months 594
Every 2 months 388
Every 1 year 14,840
— 3610
— 29,000
metabolic panel, liver function test, prothrombin time test, partial
Base value, $ Range, %, $ Reference
low-up visit;
iopsy;
1447 723–2894 52
y tests every
y 4 weeks;
;
833 416–1666 52
y tests every
y 4 weeks;
;
1308 654–2616 52
y tests every
y 4 weeks;
traception
2197 1099–4395 52
61 31–123 52asicns
1 fol
iver b
rator
ever
eeks
eeks
rator
ever
eeks
eeks
rator
ever
s; con764 378–949 53
a
$
r
m
m
s
w
r
s
t
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883V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 7 6 – 8 8 6ness-to-pay threshold of $50,000 per QALY. We varied transition
probabilities, treatment probabilities, and utilities from 0 to 1 and
identified thresholds where the net benefit metric switched from
positive (i.e., cost-effective) to negative in relation to plausible
ranges of the variables. Finally, we varied the costs across the
ranges described above.
In addition to one-way sensitivity analyses, we analyzed sev-
eral alternative scenarios. First, we varied treatment duration
from 12 to 16 weeks for patients with genotype 2 or 3. Second,
instead of varying single probability estimates, we applied groups
of probabilities derived from the same sources to maintain rela-
tionships among probabilities. When all probabilities were not
available from a single source, we retained the probabilities from
the base-case analysis. Finally, in the third set of scenario analy-
ses, we eliminated the option for re-treatment in patients for
whom truncated therapy failed.
Finally, we performed a probabilistic sensitivity analysis to
evaluate parameter uncertainty by using a second-order Monte
Carlo simulation of 10,000 trials in which all model inputs were
varied simultaneously. For probabilities and utilities, we generally
applied beta distributions and derived distribution parameters
from published 95% confidence intervals. For chance nodes with
more than two possible outcomes, we assigned Dirichlet distribu-
tions. We assumed that unit costs were fixed.
Results
Across all genotypes, discounted quality-adjusted life expectancy
was 17.1  0.70 QALYs in the standard-duration group and 17.2 
0.70 QALYs in the response-guided group. The mean discounted
lifetime cost was $46,623  $2,483 in the standard-duration group
nd $42,354 $2,489 in the response-guided group, a cost saving of
4,269  $352 for truncated therapy. Based on point estimates,
esponse-guided therapy was economically dominant and re-
ained so in 78.6% of the Monte Carlo simulations.
Table 6 shows the base-case results by viral genotype. Because
ost patients had genotype 1, their results mirrored the overall re-
ults. The modeled rate of sustained virologic response for patients
ith genotype 1was 39% in both the standard-duration therapy and
esponse-guided therapy groups. In a probabilistic sensitivity analy-
is, response-guided therapywaseconomically dominant in 50.5%of
he trials andwas cost saving in 100%. Response-guided therapywas
lso economically dominant for patients with genotype 2 or 3 and
Table 6 – Summary of costs, efficacy, and cost-effectivenes
Model and therapy Cost (SE), $ Incremental cost (SE)
All genotypes
Standard 46,623 (2483)
Truncated 42,354 (2489) –4269 (352)
Genotype 1
Standard 50,502 (2630)
Truncated 46,669 (2633) 3833 (393)
Genotype 2
Standard 30,055 (1147)
Truncated 23,260 (1028) 6795 (642)
Genotype 3
Standard 31,577 (1389)
Truncated 25,945 (1354) 5632 (653)
Genotype 4
Standard 43,788 (2040)
Truncated 43,960 (1973) 172 (2062)
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted lif
* All costs and utilities are discounted. Costs are expressed in 2010 Uas cost saving in 100% of the trials (Fig. 3). The modeled rates ofustainedvirologic response for genotypes 2 and3were 75%and69%
n the standard-duration therapy group and 77% and 69% in the re-
ponse-guided therapy group, respectively.
Results for genotype 4 varied from the other genotypes. The two
reatment strategies had similar costs, because themodeled efficacy
as greater in the response-guided therapy group and patientswere
xpected to survive longer. The modeled rate of sustained virologic
esponse was 60% in the standard-duration therapy group and 73%
n the response-guided therapy group. Quality-adjusted life expec-
ancy with response-guided therapy (18.6  0.8 QALYs) was greater
han with standard-duration therapy (17.8  0.8 QALYs). Estimated
osts were similar, but slightly higher with response-guided therapy
$172  2,062). As a result, the incremental cost-effectiveness ratio
ased on point estimates was $240 per QALY, but varied greatly in
robabilistic sensitivity analysis in which response-guided therapy
as economically dominant in 45.9% of the trials and cost-effective
i.e.,$50,000 per QALY) in another 46.3%.
In one-way sensitivity analyses, only the parameters for esti-
ates of primary treatment efficacy influenced the cost-effective-
QALYs (SE) Incremental QALYs (SE) ICER, $/QALY
17.11 (0.70)
17.16 (0.70) 0.05 (0.07) Dominant
16.77 (0.73)
16.77 (0.73) 0.00 (0.08) Dominant
18.62 (0.74)
18.89 (0.77) 0.27 (0.12) Dominant
18.32 (0.71)
18.47 (0.73) 0.15 (0.12) Dominant
17.83 (0.77)
18.55 (0.80) 0.72 (0.52) $240
r.
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Fig. 3 – Probabilistic sensitivity analysis by genotype. Note.
Each point on the plot corresponds to one trial in the
Monte Carlo simulation comparing the incremental
effectiveness and incremental costs of truncated therapy
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884 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 7 6 – 8 8 6ness of response-guided therapy (Table 7). When varied over pre-
specified ranges, none of the estimates of costs, disease
progression, re-treatment efficacy, or utilities altered the findings
of the base-case analysis substantially.
In the first set of scenario analyses, we increased the duration
of response-guided therapy from 12 to 16 weeks for patients with
genotype 2 or 3. The resulting lifetime costs and QALYs were sim-
ilar to those in the base-case analyses. In the second set of sce-
nario analyses, we repeated the analyses with varying input
sources for treatment efficacy. The results were sensitive to the
source of the parameter estimates for relative treatment efficacy
(data not shown). When the source indicated that standard ther-
apy had equal or greater efficacy than response-guided therapy,
response-guided therapy was no longer economically dominant.
Response-guided therapy remained the economically preferred
strategy (incremental cost-effectiveness ratio$50,000 per QALY)
when we applied parameter estimates from 50% (2 of 4) of the
available sources for genotype 1, 86% (6 of 7) of the sources for
genotype 2, 71% (5 of 7) of the sources for genotype 3, and 100%
(7 of 7) of the sources for genotype 4.
Finally, in the third set of scenario analyses, we eliminated the
option for re-treatment in patients for whom truncated therapy
failed and varied the likelihood of sustained virologic response
from 0% to 100%. These changes did not alter the choice of pre-
ferred strategy. Insensitivity to the efficacy of re-treatment was
Table 7 – Results from 1-way sensitivity analyses for treatm
Variable Baseline value
(Range), %
Genotype 1
EVR 73 (73–96)
SVR given EVR 54 (54–85)
LVL 18 (8.0–24)
RVR in LVL 39 (27–51)
SVR given RVR in LVL 89 (74–96)
EVR given no RVR 75 (75–78)
SVR given no RVR, EVR in LVL 61 (51–61)
EVR in HVL 71 (57–85)
Response at 24 weeks given EVR 75 (60–90)
SVR in HVL with EVR, response at 24 weeks 64 (51–77)
Genotype 2
SVR 75 (75–82)
RVR 69 (62–97)
SVR given RVR 83 (78–93)
SVR given nRVR 62 (53–72)
Genotype 3
SVR 69 (66–78)
RVR 62 (59–92)
SVR given RVR 83 (77–85)
SVR given nRVR 46 (39–46)
Genotype 4
EVR 68 (68–79)
SVR given EVR 88 (71–100)
RVR 21 (21–45)
SVR given RVR 86 (86–100)
EVR given nRVR 91 (65–91)
SVR given nRVR, EVR 77 (50–77)
EVR, early virologic response; HVL, high viral load; LVL, low viral loa
sustained virologic response.
* Sensitivity analyses are based on net monetary benefits with a
probability beyond which response-guided therapy is the preferred
† Results with all genotypes included in the model.
†† Genotype-specific results that reflect sensitivity analyses in four slikely due to the small proportion of the overall population af-fected. For example, in the base case, only 0.8% of the patients
with genotype 1, 11.7% of the patients with genotype 2, 10.4% of
the patients with genotype 3, and 3.0% of the patients with geno-
type 4 were eligible for re-treatment.
Discussion
Based on the best available data, response-guided therapy
based on viral genotype, baseline viral load (for patients with
genotype 1), and rapid virologic response is likely to be a cost-
saving strategy among patients with chronic HCV infection. The
benefit of response-guided therapy in this analysis was primar-
ily related to cost savings obtained by shortening treatment
duration among patients for whom the likelihood of success
was high. For example, in the overall model, only 18% of the
patients in the response-guided treatment group received trun-
cated therapy, but the rates of sustained virologic response
among those receiving truncated therapy was greater than 80%,
even among patients with genotype 1. Although the proportion
of patients receiving truncated therapy was relatively modest, a
cost saving of 10% is meaningful. For every 10 patients under-
going truncated therapy, the savings accrued could be used to
pay for 48 weeks of antiviral treatment.
Previous cost-effectiveness analyses have found similar re-
probabilities*.
eshold favoring response-
ided therapy overall, %†
Threshold favoring genotype-
specific response-guided
therapy, %††
80 76
58 56
8 13
6 24
39 67
20 51
24 40
61 66
65 70
57 61
93 82
2 44
50 70
2 39
— 73
— 51
7 74
— 34
— 84
— —
— —
— 14
— 67
— 59
VR, no rapid virologic response; RVR, rapid virologic response; SVR,
gness to pay up to $50,000 per QALY; A threshold represents the
egy.
te models.ent
Thr
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d; nR
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stratsults when assessing the relative costs and benefits of response-
885V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 7 6 – 8 8 6guided therapy. For example, Nakamura et al. [57] evaluated the
cost-effectiveness of adjusting treatment duration on the basis of
rapid virologic response in patients with genotype 1 and low viral
load and in patients with genotype 2 or 3. Similar to our analysis,
the results were sensitive to assumptions about treatment effi-
cacy. Unlike our study, the analysis combined genotypes 2 and 3
and did not include genotype 4, and it did not address parameter
uncertainty with a probabilistic sensitivity analysis. Buti et al. [58]
used decision analysis to measure the budget impact of response-
guided therapy on the Spanish health care system. Their analysis
also was limited to genotypes 1, 2, and 3 and did not include esti-
mates of lifetime costs or QALYs.
Although our results were robust with regard to variations in
costs, utilities, and estimates of disease progression, they were
sensitive to assumptions about treatment success within geno-
type. Estimates of sustained virologic response in genotype 1 and
rapid virologic response in genotypes 2 and 3 came from different
sources than the other response probabilities used in the model
and thus may affect the internal validity of the model. To address
this limitation, we attempted to calibrate the model so that it
would reflect the treatment efficacy reported in the literature.
Also, despite the fact that treatment probabilities came from a
single randomized trial for genotype 4, the results for genotype 4
are not as robust, as reflected in the wider confidence intervals in
the probabilistic sensitivity analysis.
In addition to understanding the impact of treatment data on
the internal validity of the model, it is important to note that the
evidence supporting the use of rapid virologic response to guide
treatment duration is inconsistent. According to the framework
proposed by Simon et al. [59] for the evaluation of prognostic and
predictive biomarkers, most of the evidence used in our analy-
sis comes from categories B (prospective studies using archived
samples) and C (prospective observational studies) with incon-
sistent results; thus, the level of evidence is III. The level of
evidence would be strengthened with additional data from ran-
domized trials explicitly assessing the efficacy of response-
guided treatment. Nevertheless, the model reflects the best
available evidence and is consistent with expert consensus, and
so we believe that the results can inform policy discussions and
future trial design.
Because the model identified treatment response probabilities
as important, future studies may need to consider additional fac-
tors that influence treatment response. For example, we did not
vary treatment efficacy on the basis of patient characteristics such
as stage of fibrosis at baseline [26]. We also did not account for
patient race, though race is a predictor of treatment efficacy [60].
In addition, two innovations in HCV therapymay affect treatment
response. The first is the discovery of genetic predictors of treat-
ment success, specifically IL28B [61]. This predictor and others
may allowmore refined stratification of patients and change even
the standard approach to HCV therapy. The second innovation is
the development of direct-acting antiviral therapy; the NS3 pro-
tease inhibitors boceprevir and telaprevir have recently been ap-
proved in the United States and the European Union. Available
data suggest that therapeutic regimens that include these drugs
will bemore effective than currently available regimens, although
they will also come with additional costs and side effects [62,63].
Current modeling efforts are assessing the cost-effectiveness of
these new treatment regimens. Nevertheless, dual therapy with
pegylated interferon and ribavirin will remain the sole choice for
many patients, including those with genotypes 2, 3, and 4 for
whom the protease inhibitors are not approved, aswell as patients
with all genotypes for whom the costs of protease inhibitors are
prohibitive. For these groups, our analysis remains relevant in
helping guide treatment decisions.In conclusion, based on the best available data, response-
guided therapy is likely to be a cost-effective treatment strategy
for patientswith chronicHCV infection.Most patients in this strat-
egy would continue to receive standard-duration therapy, and the
cost savings and utility benefits come primarily from shortening
therapy in the small subgroup of patients who have a high likeli-
hood of treatment success. Further stratification of patients with
HCV infection by using a combination of patient characteristics,
virus characteristics, and the interaction of the two may provide
additional opportunities to reduce both the cost and burden of
therapy. New therapies will provide additional options for person-
alized care, and future comparative effectiveness trials assessing
treatment strategies should consider truncated therapy in appro-
priately selected patients. Until those trials are completed, deci-
sion analysis may be helpful in optimizing resource allocation in
the era of personalized therapy for chronic HCV infection.
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